Why the study?
Chemotherapeutic agents like anthracyclines and HER2/ErbB2 inhibitors cause significant cardiovascular toxicity, necessitating an understanding of basic diagnostic and treatment strategies among oncologists and cardiologists.
What are the cardiotoxic effects of anthracyclines and anti-HER2/neu therapy in oncological patients and how should they be managed?
What are the cardiotoxic effects of anthracyclines and anti-HER2/neu therapy in oncological patients and how should they be managed?
Answers are grounded in this paper and cite their sources.
Anthracyclines and anti-HER2/neu therapies pose significant cardiotoxic risks, necessitating awareness and management strategies by both oncologists and cardiologists.
Adverse events affecting the cardiovascular system are one of the most serious problems in the general management of patients with oncological diseases, since they can jeopardize the success in the treatment of malignant neoplasms. Despite modern methods of treatment, some chemotherapeutic drugs, such as anthracyclines, HER2 /ErbB2 inhibitors can have a pronounced effect on the cardiovascular system. These toxic effects lead to cardiac arrhythmia, heart failure, vascular toxicity and even death. It is important for oncologists and cardiologists to understand the basic diagnostic and treatment strategies that should be used in the event of toxicity of this kind.
No takes yet. Share an insight, caveat, or question.
Rusanov et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: